 | • レポートコード：MRC2303I0115 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査レポートでは、世界の薬剤溶出性バルーン市場規模が、予測期間中に年平均18%で成長すると予測しています。本レポートは、薬剤溶出性バルーンの世界市場について調べ、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品別（冠動脈薬剤溶出性バルーン、末梢薬剤溶出バルーン、その他）分析、技術別（フリーパック、トランスパック、エンデュラコート、その他）分析、エンドユーザー別（病院、外来手術センター、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来の動向などを以下の構成でまとめています。また、Medtronic PLC、Boston Scientific Corporation、Becton, Dickson and Company、Terumo Corporation、Koninklijke Philips NV、Cook Group Incorporated、Biotronik、B. Braun Melsungen AG、SurModics Inc.などの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の薬剤溶出性バルーン市場規模：製品別 - 冠動脈薬剤溶出性バルーンの市場規模 - 末梢薬剤溶出バルーンの市場規模 - その他製品の市場規模 ・世界の薬剤溶出性バルーン市場規模：技術別 - フリーパック技術の市場規模 - トランスパック技術の市場規模 - エンデュラコート技術の市場規模 - その他技術の市場規模 ・世界の出性バルーン市場規模：エンドユーザー別 - 病院における市場規模 - 外来手術センターにおける市場規模 - その他における市場規模 ・世界の薬剤溶出性バルーン市場規模：地域別 - 北米の薬剤溶出性バルーン市場規模 アメリカの薬剤溶出性バルーン市場規模 カナダの薬剤溶出性バルーン市場規模 メキシコの薬剤溶出性バルーン市場規模 … - ヨーロッパの薬剤溶出性バルーン市場規模 ドイツの薬剤溶出性バルーン市場規模 イギリスの薬剤溶出性バルーン市場規模 フランスの薬剤溶出性バルーン市場規模 … - アジア太平洋の薬剤溶出性バルーン市場規模 中国の薬剤溶出性バルーン市場規模 日本の薬剤溶出性バルーン市場規模 インドの薬剤溶出性バルーン市場規模 … - 中東/南米の薬剤溶出性バルーン市場規模 南アフリカの薬剤溶出性バルーン市場規模 ブラジルの薬剤溶出性バルーン市場規模 アルゼンチンの薬剤溶出性バルーン市場規模 … - その他地域の薬剤溶出性バルーン市場規模 ・競争状況 ・市場機会・将来の動向 |
The drug-eluting balloon market is expected to register an approximate CAGR of 18% during the forecast period.
COVID-19 had a significant impact on the growth of the market. The COVID-19 pandemic has negatively affected surgical procedures due to the high rate of infection and lockdown restrictions. A delay in diagnosis and treatments was also observed in patients with cardiovascular diseases as a result of a reduction of footfall in hospitals and diagnostic centers, which impacted the market studied as well. Such delay in diagnosis and treatment led to a slight decrease in the demand for drug-eluting balloons, thereby affecting the growth of the market. For instance, according to a research study published in NCBI in March 2022, there was a 52.7% reduction in the volume of adult cardiac surgeries and a 65.5% reduction in elective cases, which indicated the negative impact of COVID-19 on cardiac surgical procedures. However, another NCBI research study published in April 2021 stated that COVID-19 could increase the development of atherosclerosis due to ACE2, which is also a receptor for the SARS-CoV-2 virus. Thus, the long-term effect of COVID-19 on the human body may increase the prevalence of atherosclerosis and other cardiac diseases, which is expected to increase the demand for drug-eluting balloons, thereby by contributing to the growth of the market.
The increasing incidence of coronary and peripheral artery diseases around the world is expected to boost the market’s growth. In addition, increasing research and development supported by government and private institutions and continuous initiatives about awareness regarding heart diseases are fuelling the market growth.
According to the Australian Institute of Health and Welfare, in May 2022, out of 11.8 million admissions, 7.0% of hospitalizations involved a stay in the intensive care unit, and 3.8% of hospitalizations involved cardiovascular diseases. According to the American Heart Association 2021 report, peripheral artery disease (PAD) affects more than 200 million people worldwide and is associated with high mortality and morbidity. Moreover, the increasing geriatric population, which is prone to cardiovascular diseases, and growing healthcare spending are projected to bolster market growth. For instance, according to the research study published in December 2021, by Elsevier, for older people aged 45 and above, the overall self-reported prevalence of diagnosed cardiovascular diseases (CVDs) was 29.4%. The prevalence rate increased with age, from 22% in the 45–54 age group to 38% in the 70+ age group, showing that the senior population is at high risk of having CVDs. Such prevalence of various cardiovascular conditions is expected to drive the demand for drug-eluting balloons as they are used to treat various cardiovascular conditions, thereby helping in the recovery of affected patients.
However, the high cost of development and commercialization of drug-eluting balloons, coupled with stringent regulatory procedures, are hampering the market growth.
Drug Eluting Balloon Market Trends
Peripheral Drug-eluting Balloons are Expected to Grow at a Healthy Rate Over the Forecast Period
Drug-eluting balloons play an important role in the treatment of peripheral artery diseases. The growing prevalence of peripheral artery diseases, coupled with the increasing geriatric population, is expected to boost segment growth.
According to the American Heart Association 2021 report, peripheral artery disease (PAD) affects more than 200 million people worldwide and is associated with high mortality and morbidity. With the aging global population, PAD may likely become increasingly common. Statistics show that PADs are increasing at a faster pace, which is ultimately driving the segment for peripheral drug-eluting balloons. Another scientific study published by the American Heart Association in August 2021 stated that lower extremity PAD affects more than 230 million people worldwide and is linked to an elevated risk of several unfavorable clinical outcomes (including cardiovascular diseases like coronary heart disease and stroke and limb outcomes, like amputee status). The increased incidence of PAD is expected to boost the use of peripheral drug-eluting balloons over the forecast period.
The segment for peripheral drug-eluting balloons is expected to have a significant share owing to the increased usage of drug-eluting balloons in the treatment of peripheral artery diseases and growing R&D in expanding the indications, and new product launches in the peripheral artery segment.
The anticipated product launches, coupled with the development of innovative coating and balloon technologies, are expected to boost the segment’s growth over the forecast period.
North America is Expected to Have Significant Market Share Over the Forecast Period
The major factors attributing to the growth are a sedentary lifestyle lacking physical activity, lack of proper diet, anxiety, and stress resulting in chronic diseases, such as diabetes and obesity, leading to an increase in the prevalence of multiple cardiovascular diseases like coronary artery disease, strokes, and atrial fibrillation.
The data updated by Cedars-Sinai in January 2022 showed that coronary artery bypass graft surgery (CABG), also known as coronary artery bypass, or bypass surgery, is the most common type of heart surgery. More than 300,000 people have successful bypass surgeries in the United States each year. Such a burden of various cardiovascular disease-related surgical procedures is expected to drive the demand for drug-eluting balloons and provide lucrative opportunities for the growth of the market in this region.
In addition, the Centers for Disease Control and Prevention (CDC) data updated in July 2022 showed that coronary heart disease is the most common type of heart disease, and approximately 20.1 million adults of age 20 and older had the disease in the United States. Per the CDC data, every 40 seconds, someone suffers from a heart attack, and nearly 805,000 people in the United States have a heart attack every year. Thus, the high burden of cardiovascular diseases demands the availability of drug-eluting balloons.
The presence of a large pool of people with heart diseases and growing healthcare spending, especially in emerging countries of North America, are expected to boost the market growth.
Drug Eluting Balloon Market Competitor Analysis
The drug-eluting balloon market is moderately consolidated and competitive. Companies are focusing on innovating balloon technologies and expanding product indications to increase their market share. The key market players operating in the market include Medtronic PLC, Boston Scientific Corporation, Becton, Dickson and Company, Terumo Corporation, and Koninklijke Philips NV, among others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Prevalence of Peripheral and Coronary Artery Diseases
4.2.2 Rising Geriatric Population Leading to Cardiovascular Diseases
4.3 Market Restraints
4.3.1 High Cost of Development and Commercialization of Drug-eluting Balloons
4.3.2 Adverse Effects and Product Recalls
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Product
5.1.1 Coronary Drug-eluting Balloon
5.1.2 Peripheral Drug-eluting Balloon
5.1.3 Other Products (Renal/Urology)
5.2 By Technology
5.2.1 FreePac
5.2.2 TransPac
5.2.3 EnduraCoat
5.2.4 Other Technologies
5.3 By End User
5.3.1 Hospitals
5.3.2 Ambulatory Surgical Centers
5.3.3 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Medtronic PLC
6.1.2 Boston Scientific Corporation
6.1.3 Becton, Dickson and Company
6.1.4 Terumo Corporation
6.1.5 Koninklijke Philips NV
6.1.6 Cook Group Incorporated
6.1.7 Biotronik
6.1.8 B. Braun Melsungen AG
6.1.9 SurModics Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS